Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 8.05
- Piotroski Score 4.00
- Grade Neutral
- Symbol (MOLN)
- Company Molecular Partners AG
- Price $5.75
- Changes Percentage (-4.65%)
- Change -$0.28
- Day Low $5.73
- Day High $6.04
- Year High $12.70
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/06/2025
- Fiscal Year End N/A
- Average Stock Price Target $29.00
- High Stock Price Target $29.00
- Low Stock Price Target $29.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.00
- Trailing P/E Ratio -2.03
- Forward P/E Ratio -2.03
- P/E Growth -2.03
- Net Income $-61,984,000
Income Statement
Quarterly
Annual
Latest News of MOLN
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Is Molecular Partners (VTX:MOLN) In A Good Position To Deliver On Growth Plans?
Investors in companies like Molecular Partners should monitor cash burn rates to assess financial stability. With a cash runway of 2.5 years, the company seems stable, but potential capital raising is...
By Yahoo! Finance | 1 month ago -
Investors in Molecular Partners (VTX:MOLN) have unfortunately lost 69% over the last three years
Molecular Partners AG's share price rose 68% in the last quarter after a 69% decline over three years. Revenue dropped by 11% annually, impacting profits. The company's future growth and financial sta...
By Yahoo! Finance | 2 months ago
